Determination of inmune response and inflammation mediators in tears: Changes in dry eye and glaucoma as compared to healthy controls.
Por:
Benitez-Del-Castillo Sánchez J, Morillo-Rojas MD, Galbis-Estrada C and Pinazo-Duran MD
Publicada:
1 may 2017
Ahead of Print:
3 feb 2017
Categoría:
Ophthalmology
Resumen:
OBJECTIVE: To determine the expression profile of immune response and
inflammation (IRI) mediator molecules in tears from patients with dry
eye (DE), and those suspected of having or have primary open-angle
glaucoma (POAG) under treatment and compare them with healthy controls.
METHODS: A prospective observational cohort study including 107
participants sub-divided into: healthy controls (CG; n=30), patients
with DE (DEG; n=41) and patients suspected of having or have POAG and on
hypotensive treatment (POAG-G; n=36). Tear samples were collected by
capillary to be processed using a multi-immunoassay system based on flow
cytometry (Luminex R-200 ), in order to determine the interleukins (IL):
1beta, 2, 4, 5, 6, and 10, and the growth factors: Tumour necrosis alpha
(TNF-alpha), vascular endothelial (VEGF), and granulocyte-macrophage
colony stimulating- (GM-CSF). Data were processed using the SPSS 20.0
program.
RESULTS: Molecules that significantly increased in tears from DEG vs.
POAG-G patients were: IL-1 (P=.01), IL-6 (P=.004), IL-10 (P=.04),
whereas VEGF significantly decreased in the DEG. The POAG-G showed
significantly higher IL-6 values (P<.0001) as compared to the CG. When
comparing both the DEG and POAG-G, significant differences were observed
in tear expression of IL-4 (P=.004), IL-6 (P=.002), TNF-alpha (P=.03),
GM-CSF (P=.03), and VEGF (P=.002).
CONCLUSIONS: The increased expression of IRI mediators in tears from
patients with DE or POAG strongly demonstrated the importance of immune
response in both pathologies. However, the different molecules involved
also suggest distinct signalling pathways for these processes that still
require further research.
Filiaciones:
Benitez-Del-Castillo Sánchez J:
Departamento de Oftalmología, Hospital de Jerez, Jerez de la Frontera, España.
Morillo-Rojas MD:
Departamento de Oftalmología, Hospital de Jerez, Jerez de la Frontera, España
:
Unidad de Investigación de Oftalmología Santiago Grisolía, Hospital Universitario Dr. Peset, Valencia, España
:
Unidad de Investigación de Oftalmología Santiago Grisolía, Hospital Universitario Dr. Peset, Valencia, España
|